Compass Therapeutics, Inc. — Director's Dealing 2021

Jun 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Compass Therapeutics, Inc. (CMPX)
CIK: 0001738021
Period of Report: 2021-06-25

Reporting Person: Toledano Miranda Jayne (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-25	Common Stock, $.0001 Par Value	J	1791549	—	Acquired	1791549	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-25	Stock Option (Right to Buy)	$4.9	A	50000	Acquired		Common Stock, $.0001 Par Value (50000)	Direct

Footnotes

F1: The reporting person acquired 1,791,549 shares of the issuer's common stock as consideration in connection with the acquisition of TRIGR Therapeutics, Inc. by the issuer. The merger agreement, which was entered into on May 13, 2021, placed a negotiated value on the issuer's common stock of $5.85 a share. Of the 1,791,549 shares issued to the reporting person in the merger, 283,648 shares are currently being held in escrow and are subject to forfeiture for the purposes described in the merger agreement.

F2: The option has a term of 10 years and vest in equal monthly installments over the 48 month period commencing on July 25, 2021.